Valirx (VAL)

 

Latest News

Convertible Loan Facility

RNS Number: 7140N ValiRx PLC 11 August 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK., 11 August 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has drawn down US$400,000 of the third tranche of its Convertible Loan Facility (announced on 02 September 2016) wi...

Conversion of Loan Note

RNS Number: 8102M ValiRx PLC 02 August 2017 ValiRx Plc ("ValiRx" or the "Company") Loan Note Conversion and Issue of Equity London, UK ., 2 August 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation...

ValiRx signs first product licensing agreement

ValiRx (VAL), a clinical stage biotechnology company, has signed a licensing agreement with Mystic Pharmaceuticals in B...

Licencing Agreement

RNS Number: 3478M ValiRx PLC 28 July 2017 ValiRx Plc ("ValiRx" or the "Company") VALIRX AND MYSTIC PHARMACEUTICALS SIGN LICENCE AGREEMENT London, UK ., 28 July 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce that ValiRx has signed a licensing agreement with Mystic Pharmaceuticals L...

All News

DateHeadlineSource
11-08-17Convertible Loan FacilityRNS
02-08-17Conversion of Loan NoteRNS
28-07-17ValiRx signs first product licensing agreementStockMarketWire
28-07-17Licencing AgreementRNS
22-06-17Formation of & Appointments to an Advisory BoardRNS
15-06-17ValiSeek Development Update - Recruitment ClosesRNS
15-06-17ValiRx - ValiSeek Clinical Development UpdateBRR Media
01-06-17ValiRx updates on Yorkville CLN ConversionStockMarketWire
01-06-17Yorkville CLN ConversionRNS
31-05-17Hardman Research:Developing novel cancer therapiesRNS
30-05-17All resolutions passed at AGM of ValiRxStockMarketWire
30-05-17Result of AGMRNS
24-05-17ValiSeek's patent allowed in AustraliaStockMarketWire
24-05-17NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCERNS
08-05-17Broker Forecast - Beaufort Securities issues a broker note on ValiRx PLCStockMarketWire
08-05-17ValiRx - Final Results BRR Media
05-05-17Notice of AGMRNS
05-05-17ValiRx widens FY pretax loss from continuing ops.StockMarketWire
05-05-17Final ResultsRNS
27-04-17Re: SHARES Magazine Supplement on ValiRx websiteRNS
19-04-17Change of Registered OfficeRNS
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
15-03-17Director/PDMR ShareholdingRNS
08-03-17ValiSeek Clinical Development UpdateRNS
08-03-17ValiRX - Projects updateBRR Media
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director Deals - ValiRx PLC (VAL)StockMarketWire
02-03-17Director/PDMR ShareholdingRNS
01-03-17ValiRx raises £1.16m via placingStockMarketWire
01-03-17Placing to raise ?1.16m and Proposed SubscriptionRNS
28-02-17Publication of Peer-Reviewed Articles on VAL401RNS
11-01-17ValiRx notes positive VAL201 clinical trialStockMarketWire
11-01-17CLINICAL TRIAL UPDATE - Positive VAL201 ResultsRNS
30-12-16ValiRx notes Yorkville CLN conversionStockMarketWire
30-12-16Yorkville CLN ConversionRNS
08-12-16ValiRx says European patent granted for VAL201StockMarketWire
08-12-16European Patent Granted for Lead Compound VAL201RNS

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory